Eating disorders — anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), avoidant/restrictive food intake disorder (ARFID), and other specified feeding or eating disorders (OSFED) — affect roughly 2.7% of Canadians lifetime (Statistics Canada CCHS), with substantially higher prevalence in adolescent and young-adult women. Anorexia nervosa has the highest mortality rate of any psychiatric disorder. Standard-of-care eating disorder treatment — specialized inpatient/residential/intensive outpatient programs, family-based therapy (FBT, "Maudsley") for adolescent AN, CBT-E (enhanced cognitive behavioural therapy) for BN/BED, DBT (dialectical behaviour therapy), medical stabilization, nutritional rehabilitation, SSRIs (selectively for BN/BED, less established for AN), antipsychotics (selectively) — is foundational. This article is a Canadian evidence-and-pathway guide to psychedelic-assisted therapy as an emerging adjunct: psilocybin for anorexia nervosa has the strongest published emerging evidence (Peck et al. 2023 Imperial College pilot; Compass COMP360-AN); MDMA-AT for ED with smaller emerging signal; off-label ketamine with ED comorbidity uses for depression/anxiety. No psychedelic-assisted therapy is approved for eating disorders. Comprehensive ED treatment integration is non-negotiable.
Key takeaways
- Eating disorders affect ~2.7% of Canadians lifetime. AN has the highest mortality of any psychiatric disorder.
- Standard-of-care ED treatment is foundational: specialized programs, FBT/CBT-E/DBT psychotherapy, medical stabilization, nutritional rehabilitation, selective psychopharmacology.
- Psilocybin for AN has the strongest published emerging evidence: Peck et al. 2023 (Imperial College) pilot study of psilocybin-assisted therapy for AN; small sample but feasibility and safety signal.
- Compass COMP360-AN program: ongoing investigational program for AN.
- MDMA-AT for ED: emerging signal; relevant for ED with comorbid PTSD given documented trauma overlap.
- Off-label ketamine for ED comorbidity: use cases primarily for depression/anxiety comorbid with ED; not directly ED-targeted.
- No psychedelic-assisted therapy is approved or routinely available for eating disorders.
- Medical stability is non-negotiable before any psychedelic-assisted therapy consideration — particularly for AN populations.
- Psychedelic-assisted therapy is NOT a replacement for comprehensive ED treatment. Family-based therapy, CBT-E, specialized ED programs remain foundational.
Defining eating disorders
DSM-5 eating disorders:
- Anorexia nervosa (AN): restriction leading to significantly low body weight; intense fear of weight gain; body image disturbance. Restricting type and binge-eating/purging type.
- Bulimia nervosa (BN): recurrent binge episodes followed by inappropriate compensatory behaviors (vomiting, laxative misuse, fasting, excessive exercise)
- Binge eating disorder (BED): recurrent binge episodes without compensatory behaviors
- ARFID: avoidant/restrictive food intake disorder; differs from AN in absence of body-image disturbance
- OSFED: other specified feeding or eating disorders
AN has the highest mortality rate of any psychiatric disorder, both from medical complications and suicide. Comprehensive medical stability is non-negotiable.
The eating disorder evidence map for psychedelic-assisted therapy
Psilocybin for AN — strongest emerging evidence
- Peck SK, Shao S, Gruen T, et al. 2023 (PMID 37464048): Imperial College pilot study of psilocybin-assisted therapy for anorexia nervosa. Small sample (n=10); feasibility and safety signal; exploratory efficacy outcomes.
- Compass Pathways COMP360-AN: investigational phase 2 program.
- Atira Pharmaceuticals: also exploring AN indication.
- Mechanism rationale: 5-HT2A receptor system implicated in cognitive flexibility, body-image rigidity, and reward processing — all relevant to AN psychopathology.
MDMA-AT for ED — emerging
- Brewerton TD, Wang JB, Lafrance A, et al.: emerging analyses of MDMA-AT for PTSD with comorbid ED suggest signal. Trauma is a documented risk factor for ED development; addressing trauma may benefit ED outcomes.
- MDMA-AT for AN/BN primary indication: smaller emerging signal.
Off-label ketamine for ED comorbidity
- Use cases: primarily for depression/anxiety comorbid with ED rather than directly ED-targeted
- Real-world Canadian KAP: some carefully-screened ED populations have received ketamine for comorbid TRD
- Medical stability prerequisite: ED medical instability (electrolyte abnormalities, cardiovascular fragility, severe malnutrition) typically excludes ketamine until stabilized
Spravato — NOT for eating disorders
Spravato is approved for TRD only. Off-label use for ED is rare given absence of direct evidence and strong concerns about ED population safety.
For more detail see the Ketamine Therapy in Canada guide.
Decision framework — comprehensive ED treatment integration
Psychedelic-assisted therapy for ED is appropriately considered as adjunct to comprehensive ED treatment, not a replacement.
| Step | Question | Consequence |
|---|---|---|
| 1 | Is medical stability established? | If no: medical stabilization first; psychedelic-assisted therapy not appropriate |
| 2 | Is patient in active comprehensive ED treatment (FBT, CBT-E, specialized program)? | If no: pursue first-line ED treatment |
| 3 | What's BMI and nutritional status? | Severe malnutrition or severe dehydration are contraindications |
| 4 | Is there suicidality or severe medical risk? | Comprehensive psychiatric care + medical stabilization first |
| 5 | What ED comorbidities? (TRD, PTSD, anxiety, OCD, SUD) | Comorbidity may inform substance choice |
Canadian access pathways
Comprehensive ED treatment first
- Provincial specialized ED programs: Sunnybrook Eating Disorders Program (Toronto), BC Children's Hospital Eating Disorders Program, Alberta Health Services ED Program, Hôpital Sainte-Justine (pediatric Quebec), CHUM/Montreal General programs, Manitoba Adult Eating Disorders Program
- Inpatient/residential/intensive outpatient continuum: medical stabilization, nutritional rehabilitation, structured psychotherapy
- NIED (National Initiative for Eating Disorders): Canadian patient/family resource
Psychedelic-assisted therapy adjunct pathways
- Out-of-pocket dominantly: ED-specific psychedelic-assisted therapy is investigational and rarely covered
- Psilocybin SAP: case-by-case Health Canada approval; ED-primary indications less commonly approved than for end-of-life distress or TRD
- Off-label ketamine: limited use for medically-stable ED patients with comorbid TRD
What the evidence does NOT say
- No psychedelic-assisted therapy is approved or routinely available for eating disorders in Canada.
- Peck 2023 Imperial College pilot is feasibility/safety signal, not pivotal evidence. Phase 3 ED-specific trials do not yet exist.
- Effect sizes: small sample studies do not yet establish meaningful clinical effect estimates.
- Comprehensive ED treatment is foundational. Psychedelic-assisted therapy without ED-specialized care concurrent is not the studied intervention.
- Medical stability prerequisites: severe malnutrition, electrolyte abnormalities, cardiovascular fragility are contraindications to psychedelic-assisted therapy.
- Family/caregiver context: AN in adolescents specifically benefits from family-based therapy (FBT/Maudsley) — psychedelic-assisted therapy does not replace this.
- Trauma-comorbidity: ED patients have high trauma comorbidity; MDMA-AT for PTSD with comorbid ED is an emerging area but not a primary ED treatment.
How ATMA CENA works with ED patients
ATMA CENA's ED pathway:
- Comprehensive intake: ED history, current treatment team, medical stability, BMI/nutritional status, comorbidities, prior treatments
- ED specialist coordination is non-negotiable: ATMA CENA will not work with ED patients without active comprehensive ED treatment team in place
- Three-phase model: preparation + dosing + integration — adapted for ED context with explicit attention to body-image and food-related triggers
- coordinated care: ED specialist remains primary therapeutic relationship; ATMA CENA layers on top
- Honest framing: ATMA CENA will route ED patients to first-line evidence-based treatments before psychedelic-assisted therapy
Patients considering this pathway can book a free information call to discuss eligibility with our clinical team.
Frequently asked questions
What's the strongest psilocybin ED evidence? Peck et al. 2023 Imperial College pilot study of psilocybin-assisted therapy for anorexia nervosa. Small sample (n=10); feasibility and safety signal; exploratory efficacy outcomes. Compass Pathways COMP360-AN program ongoing.
Can I do ketamine therapy if I have an eating disorder? Possibly — but only with medical stability, established comprehensive ED treatment team, and careful screening. Active medical instability (severe malnutrition, electrolyte abnormalities, cardiovascular fragility) is a contraindication.
What about psilocybin for bulimia or binge eating disorder? Smaller emerging evidence for BN/BED than for AN. Investigational only.
What about MDMA-AT for ED? Emerging signal particularly for ED with comorbid PTSD. Trauma is a documented risk factor for ED development; addressing trauma may benefit ED outcomes. Not yet pivotal evidence for ED primary indication.
Is psilocybin a replacement for comprehensive ED treatment? No. Psychedelic-assisted therapy is appropriately considered as adjunct to comprehensive ED treatment, not a replacement. Family-based therapy, CBT-E, specialized ED programs remain foundational.
What if I'm in active ED treatment and want to add psychedelic-assisted therapy? The decision should involve your ED specialist team. Comprehensive coordination is essential — psychedelic-assisted therapy without ED-specialized care concurrent is not the studied intervention.
What if I'm medically unstable? Medical stabilization first. Severe malnutrition, electrolyte abnormalities, cardiovascular fragility are contraindications to psychedelic-assisted therapy. Specialized ED programs provide medical stabilization.
What about adolescent ED patients? Adolescents are typically excluded from psychedelic-assisted therapy RCTs and SAP applications. Family-based therapy (FBT/Maudsley) is first-line for adolescent AN. ATMA CENA works with adult populations; adolescent ED patients should be in specialized adolescent ED programs.
What if I have ED with comorbid TRD or PTSD? The comorbidity may inform clinical decisions. ED-specialist coordination remains essential. Off-label ketamine for medically-stable ED + TRD has been used in carefully-screened cases. MDMA-AT for PTSD with comorbid ED is an emerging area.
What's the cost?
- Psilocybin SAP for ED indications: variable; clinical hours separate
- Off-label ketamine for ED + TRD comorbidity: ~$400–$1,500/session
- Insurance coverage for ED-specific psychedelic-assisted therapy is essentially non-existent.
Sources
- Peck SK, Shao S, Gruen T, et al. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nature Medicine, 29(8):1947-1953. PMID: 37464048.
- Compass Pathways — COMP360-AN program: https://compasspathways.com/our-research/anorexia-nervosa/
- Brewerton TD. (2022). Mechanisms by which adverse childhood experiences, other traumas and PTSD influence the health and well-being of individuals with eating disorders throughout the life span. J Eat Disord, 10(1):162. PMID: 36372878.
- Lock J, Le Grange D, Agras WS, Dare C. (2010). Treatment Manual for Anorexia Nervosa: A Family-Based Approach (FBT/Maudsley). Guilford Press.
- Fairburn CG. (2008). Cognitive Behavior Therapy and Eating Disorders (CBT-E). Guilford Press.
- Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
- National Eating Disorder Information Centre (NEDIC) Canada: https://nedic.ca/
- National Initiative for Eating Disorders (NIED) Canada: https://nied.ca/
- Academy for Eating Disorders (AED) — Critical Points for Early Recognition and Medical Risk Management: https://www.aedweb.org/
- Couturier J, Isserlin L, Norris M, et al. (2020). Canadian practice guidelines for the treatment of children and adolescents with eating disorders. J Eat Disord, 8:4. PMID: 32021688.
- Statistics Canada — CCHS Mental Health Component: https://www150.statcan.gc.ca/
- Foldi CJ, Liknaitzky P, Williams M, Oldfield BJ. (2020). Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models. Front Neurosci, 14:43. PMID: 32116528.
Related articles
- PTSD and Psychedelic-Assisted Therapy
- Anxiety Disorders and Psychedelic-Assisted Therapy
- Treatment-Resistant Depression and Psychedelic-Assisted Therapy
- Concurrent Disorders and Psychedelic-Assisted Therapy
- Psilocybin Therapy in Canada
- MDMA-Assisted Therapy in Canada
- Insurance Coverage for Psychedelic-Assisted Therapy in Canada
Last updated: 2026-05-06